News

New Agents for Prevention of Ultraviolet-Induced Nonmelanoma Skin Cancer

In the United States alone, an estimated 3.5 million new cases of cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC) are diagnosed each year in more than 2 million people.


 

William L. Camp, MD, MPH, Jennifer W. Turnham, BS, Mohammad Athar, PhD, and Craig A. Elmets, MD

With the incidence of nonmelanoma skin cancer on the rise, current prevention methods, such as the use of sunscreens, have yet to prove adequate to reverse this trend. There has been considerable interest in identifying compounds that will inhibit or reverse the biochemical changes required for skin cancers to develop, either by pharmacologic intervention or by dietary manipulation. By targeting different pathways identified as important in the pathogenesis of nonmelanoma skin cancers, a combination approach with multiple agents or the addition of chemopreventative agents to topical sunscreens may offer the potential for novel and synergistic therapies in treating nonmelanoma skin cancer.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

New Options for Field Therapy: MAL-PDT Plus Red LED
MDedge Dermatology
Blog: Skin Cancer Screening RV Makes AAD Pit Stop
MDedge Dermatology
AAD: Melanoma Underreported to Cancer Registries
MDedge Dermatology
Percutaneous Hepatic Perfusion Boosts Melanoma Response
MDedge Dermatology
AAD: Skin Cancer Incidence Continuing to Rise
MDedge Dermatology
The Role of Targeted Molecular Inhibitors in the Management of Advanced Nonmelanoma Skin Cancer
MDedge Dermatology
Merkel Cell Carcinoma: Update and Review
MDedge Dermatology
Current Approaches to Skin Cancer Management in Organ Transplant Recipients
MDedge Dermatology
Update on the Management of High-Risk Squamous Cell Carcinoma
MDedge Dermatology
Do Lasers or Topicals Really Work for Nonmelanoma Skin Cancers?
MDedge Dermatology